Farmas USA

SGYP 

Se empieza a calentar para su cita para nuevas apliaciones de su ya aprobado  y en el mercado medicamento TRULANCE 

En grafico diaro empieza a hacer Golden Cross MME20/MME50 y el MACD ha despegar 

2da vela alcista hoy

--

H.C. Wainwright analyst Ram Selvaraju likes the shift in leadership, and believes both this and the forthcoming date with destiny for Trulance’s supplemental New Drug Application (sNDA) in constipation-predominant irritable bowel syndrome (IBS-C) come January 24th will prove to also “spur interest” as a short-term “regulatory catalyst.”

https://www.smarteranalyst.com/2018/01/09/synergy-pharmaceuticals-inc-sgyp-savvy-leadership-turnover-upcoming-trulance-approval-ibs-c-bull-confident/

--

Alguna otra opinion por aqui 

SGYP

Yo estoy saliendo a 2.40, por ahora solo la mitad de la posición...

MLNT

Dentro a 16.90

SGYP

Fuera a 2.40  +1450$

SGYP en mi caso la espero en 2 ...si llega a darse ...que lo dudo, pero realmente me siento más cómodo entrando en los valores que me marco a pesar de sus caídas ,que montarme al tren en plena subida ...se que es lo contrario de lo recomendable por los analistas , pero es mi sistema ....mira TEVA ya va por los 21 y subiendo ...pero en mi caso me baje en 4 estaciones antes del destino ( con buenos pluses)me alegro por los que siguen dentro...que tienen los 25 a tiro de piedra ....a lo dicho , en mi caso SGYP de momento sigue monitorizada 😉

SGYP

This coming Friday will reveal the first scripts of 2018 and could yield a surprise to the upside should there have been a sizable population waiting on insurance clearance for January 1st to clear through. The first quarter of 2018 is critical for Synergy, they need IBS-C approved and for an infusion of cash to keep the year from turning into a repeat of 2017 or worse. What is clear now, is that there is increasingly less room for error on the part of management being able to clear these formulary restrictions, in a timely manner, in a competitive space.

In addition, to stave off further in-roads made by the competition in gaining global market share. Any more hiccups and this could quickly develop into a mountain of a climb to reach self-sustainability. Going on the local track is fine, but the prospect of a full on mechanical failure does loom without an added sense of urgency from management here. Let us see if Troy Hamilton is the man for the mission to see things through.

https://seekingalpha.com/article/4135911-synergy-pharmaceuticals-trulance-enters-sophomore-year

no tengo tiempo. Voy fatal de tiempo. Necesito dias de más d 24horas

TGTX
Fuera a 10,60 vacaciones pagadas.
Saludos desde St. Lucia